MacroGenics Inc
Change company Symbol lookup
Select an option...
MGNX MacroGenics Inc
SMSMY Sims Ltd
DHCAU DHC Acquisition Corp
BCH Banco de Chile
NLRCF Northern Lights Resources Corp
ABM ABM Industries Inc
LVOXW LiveVox Holding Equity Warrants Exp 18 June 2026 *W EXP 06/18/2026
TY- Tri-Continental Corp
BAC Bank of America Corp
KLXE KLX Energy Services Holdings Inc
Go

Health Care : Biotechnology | Small Cap Value
Company profile

MacroGenics, Inc. is a biopharmaceutical company that is focused on developing and commercializing antibody-based therapeutics for the treatment of cancer. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. It is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Closing Price
$3.05
Day's Change
0.10 (3.39%)
Bid
--
Ask
--
B/A Size
--
Day's High
3.09
Day's Low
2.91
Volume
(Light)
Volume:
661,862

10-day average volume:
2,512,082
661,862

Display:

Providers:

UpdateCancel
6 providers
June 08, 2022
MacroGenics to Participate in Upcoming Investor Conference

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the...(Globe Newswire)

May 23, 2022
MacroGenics Announces Appointment of William Heiden to Board of Directors

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the...(Globe Newswire)

May 17, 2022
MacroGenics to Participate in Upcoming Investor Conference

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the...(Globe Newswire)

May 03, 2022
MacroGenics Provides Update on Corporate Progress and First Quarter 2022 Financial Results

EQNX::TICKER_START (NASDAQ:MGNX), EQNX::TICKER_END -- Plan to start Phase 2/3 prostate cancer study with MGC018 by year-end -- Initiated Phase 1 study of MGC018 in combination with lorigerlimab in advanced solid tumors (Globe Newswire)

April 25, 2022
MacroGenics Announces Date of First Quarter 2022 Financial Results Conference Call

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company will release its financial...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.